These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16731611)

  • 1. Reply to "IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma".
    Egervari K; Szollosi Z; Nemes Z
    J Clin Pathol; 2006 Jun; 59(6):665; author reply 665-6. PubMed ID: 16731611
    [No Abstract]   [Full Text] [Related]  

  • 2. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
    Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
    J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
    Barrett C; Magee H; O'Toole D; Daly S; Jeffers M
    J Clin Pathol; 2007 Jun; 60(6):690-3. PubMed ID: 16822876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Lottner et al. simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005; 205: 577-584.
    Szollosi Z; Egervari K; Nemes Z; Kaczur V
    J Pathol; 2005 Sep; 207(1):119-20; author reply 121-2. PubMed ID: 15920704
    [No Abstract]   [Full Text] [Related]  

  • 5. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.
    Ellis CM; Dyson MJ; Stephenson TJ; Maltby EL
    J Clin Pathol; 2005 Jul; 58(7):710-4. PubMed ID: 15976337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.
    Kovács A; Stenman G
    Pathol Res Pract; 2010 Jan; 206(1):39-42. PubMed ID: 19819642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument.
    Going JJ
    Histopathology; 2011 Aug; 59(2):333-5. PubMed ID: 21884213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.
    Skaland I; Øvestad I; Janssen EA; Klos J; Kjellevold KH; Helliesen T; Baak JP
    J Clin Pathol; 2008 Jan; 61(1):68-71. PubMed ID: 17412872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
    Ricardo SA; Milanezi F; Carvalho ST; Leitão DR; Schmitt FC
    J Clin Pathol; 2007 Sep; 60(9):1001-5. PubMed ID: 17158643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
    Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
    J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer.
    Moon YW; Jeung HC; Rha SY; Choi YH; Yang WI; Chung HC
    Breast Cancer Res Treat; 2007 Jul; 104(1):31-7. PubMed ID: 17587181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
    Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
    J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 17. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.
    Taniyama K; Ishida K; Toda T; Motoshita J; Kuraoka K; Saito A; Tani Y; Uike T; Teramoto S; Koseki M
    Breast Cancer; 2008; 15(3):231-40. PubMed ID: 18264744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
    Hofmann M; Stoss O; Shi D; Büttner R; van de Vijver M; Kim W; Ochiai A; Rüschoff J; Henkel T
    Histopathology; 2008 Jun; 52(7):797-805. PubMed ID: 18422971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.